Beyond homozygosity mapping: family-control analysis based on Hamming distance for prioritizing variants in exome sequencing by Imai, A et al.
1Scientific RepoRts | 5:12028 | DOi: 10.1038/srep12028
www.nature.com/scientificreports
Beyond Homozygosity Mapping: 
Family-Control analysis based on 
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A major challenge in current exome sequencing in autosomal recessive (AR) families is the lack of an 
effective method to prioritize single-nucleotide variants (SNVs). AR families are generally too small 
for linkage analysis, and length of homozygous regions is unreliable for identification of causative 
variants. Various common filtering steps usually result in a list of candidate variants that cannot 
be narrowed down further or ranked. To prioritize shortlisted SNVs we consider each homozygous 
candidate variant together with a set of SNVs flanking it. We compare the resulting array of 
genotypes between an affected family member and a number of control individuals and argue that, 
in a family, differences between family member and controls should be larger for a pathogenic 
variant and SNVs flanking it than for a random variant. We assess differences between arrays in 
two individuals by the Hamming distance and develop a suitable test statistic, which is expected 
to be large for a causative variant and flanking SNVs. We prioritize candidate variants based on this 
statistic and applied our approach to six patients with known pathogenic variants and found these to 
be in the top 2 to 10 percentiles of ranks.
In current sequencing of patients in autosomal recessive (AR) families, candidate disease variants are 
generally prioritized based on well-known filtering steps1,2. Homozygosity mapping is also often applied 
to identify long runs of homozygosity3, which may be interpreted as harboring segments of DNA identi-
cal by descent (IBD), but length alone is known to be a poor statistic for this purpose4. Information from 
unaffected individuals and estimating haplotype frequencies to identify ancestral haplotypes may aid in 
the identification of segments of IBD4. Here we developed a novel method to prioritize candidate variants 
in AR families based on direct comparison of segments of sequence variants between an affected family 
member and control individuals from the same population, that is, our approach works by comparing a 
single affected individual (from a small AR family) with a number of control individuals.
Consider a set of variants within d basepairs of a candidate variant. In each individual, case and 
controls, we select homozygous variant sites from sequence vcf files. We distinguish only two states, 
v/v and “not v/v”, that is, anything other than v/v, where v is the variant allele (also called the alternate 
allele). For any two individuals, we want to measure how much their two arrays of variants differ. We 
do this with the Hamming distance5,6, which is the number of elements that differ between two arrays. 
For our set of variants and selection criteria, the two individuals can exhibit the following numbers of 
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pairs of genotypes: n1 (v/v, v/v), n2 (v/v, not v/v), and n3 (not v/v, v/v). The Hamming distance is then 
equal to n2 + n3. Expressed in words, for a set of variants within d kb of a candidate locus, the Hamming 
distance between two individuals, A and B, is given by the number of homozygous variants occurring 
only in individual A plus the number of homozygous variants occurring only in individual B. To allow 
for varying numbers of basepairs flanking a candidate variant, we define a relative Hamming distance, 
or Hamming Distance Ratio, HDR = (n2 + n3)/(n1 + n2 + n3), which is our measure for distance between 
sets of variant genotypes in two individuals.
Individuals affected with a rare autosomal recessive trait tend to have parents who are related so that 
the two disease alleles tend to be identical by descent (IBD), that is, they are likely to be copies of one 
ancestral allele. Because of paucity of crossovers very close to the disease locus, SNVs in its vicinity 
also tend to be IBD and, thus, homozygous3. For this reason, we want to see whether distances between 
affected and control individuals are larger for true candidate variants than other candidate variants. 
Various approaches may be taken for such comparisons. We found the following procedure appealing 
and powerful. For an affected family member and n control individuals, we form all possible pairs of 
individuals and distinguish the n pairs containing the affected (group 1) from the n(n− 1)/2 pairs consist-
ing only of control individuals (group 2). Then we compare mean HDR values between the two groups 
by a one-sided t statistic in the expectation that, at a pathogenic variant, group 1 means exceed group 
2 means. We do this for a range of values, d = 100 kb through 1000 kb in steps of 100 kb, and retain the 
largest t value, tmax = maxd(td). The limiting values of 100 and 1000 kb were chosen empirically; in our 
experience, the maximum t statistic often occurs inside this interval. In principle, the lower limit could 
be 0 and the upper limit could be the length of the given chromosome. The main difference would gen-
erally be increased computation time.
Candidate variants are then ranked based on their tmax value, with rank 1 corresponding to the largest 
tmax value. As the number of candidate variants may differ between affected individuals, we also compute 
the percentile (top %) of the rank of the disease variant. For the data described below, calculations were 
conducted by our HDR program.
While our focus is on ranking (prioritizing) candidate variants, we calculate empirical significance 
levels (p-values) associated with a given tmax statistic (candidate variant) as follows. We create null data 
by treating each of the n control individuals in turn as a pseudo-affected individual. All other individu-
als, including the affected, then represent pseudo-control individuals. Thus, we construct n null datasets, 
each consisting of 1 pseudo-affected and n pseudo-controls in analogy to 1 affected and n controls in 
the observed data. In each of the n null datasets, we perform the analysis done on the observed data. 
For a given candidate variant, the p-value associated with the observed tmax statistic is computed as the 
proportion of null datasets with a null-tmax value at least as large as the observed tmax value. To be con-
servative, we include the observed data with the null-data, so the smallest possible significance level is 
p = 1/(n + 1). These statistical analyses can be performed with a suitably modified version of the maxstat 
program written in Pascal.
Results
As a proof of concept, we applied our approach to six patients from five different small AR fami-
lies (Fig.  1) for which the disease-causing mutation had previously been identified and published7–14 
(Table 1). Families F1, F4, F6, and OI are members of the French-Canadian population of Québec, which 
originates from approximately 8500 French settlers who immigrated more than 300 years ago15. Family 
L1 is of European ancestry. For our approach to be valid it is important that control individuals be from 
the same ethnic background as the patients. For families F1, F4, and F6, we chose 30 members of this 
same population as controls; for family OI, we had 32 control individuals available; and for family L1 
we used 30 European control individuals. As our approach currently works with one affected individual 
versus a number of controls, the two affected individuals in family L1 were considered separately. All 
control individuals had previously been investigated for reasons unrelated to the patients. All individuals, 
cases and controls, had been exome-sequenced at McGill University and Genome Québec Innovation 
Center, Montreal, after obtaining approval from the Institutional Review Board of McGill University 
and informed consent from all individuals. The detailed sequencing protocol is given in the Methods 
section. To narrow down the list of variants, we applied several filtering steps as follows: We selected 
exonic (missense, nonsense, and Indels) or splicing or UTR variants annotated as homozygous or pos-
sibly homozygous with an allele frequency < 5% in 1000 Genome and EVS databases, then removed 
variants with quality scores less than 50 or map quality score less than 20, read depths less than 5, and 
those that were seen in more than 10 individuals in our exome database of ~1200 samples. These filtering 
steps resulted in the m = 10 through 50 final candidate variants shown in Table 1.
Results obtained by our family-control analysis demonstrate that we were able to prioritize the known 
disease variants to be in the top 2% to 10% of candidate variants (Table  1), that is, the HDR method 
narrowed down the original number of shortlisted candidate variants to between 10-fold and 50-fold 
smaller lists.
The p-values for the test statistic of the true disease variant ranged from 0.0303 through 0.0645. 
Combining five independent p-values (using only one individual in family L1) by the Fisher method16,17 
(pvalues program) results in a final empirical significance level of 0.0013. Thus, we demonstrated 
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significantly larger distances between case and control individuals for homozygous pathogenic variants 
than non-pathogenic variants.
Discussion
Our approach has several advantages over existing (homozygosity mapping, HM) methods: (1) Our 
HDR method can provide a ranking of homozygous regions while HM approaches rank on the basis of 
ROH length, which is less reliable. (2) We can assess inherited regions specific to disease pedigrees more 
accurately than using heterogeneous populations by using relatively homogenous control individuals in 
the same population as family members. (3) Most HM approaches work with sliding windows of a given 
size and additional parameters like minimum number of SNPs in an ROH, minimum length of an ROH, 
and maximum number of heterozygous SNPs in an ROH. These settings may or may not be optimal; 
on the other hand, our HDR method employs a single estimated parameter for prioritizing candidate 
variants. Thus, the HDR approach does not require any parameters that need to be fixed at the outset. A 
limitation of our approach is that control individuals are required while HM may be carried out on single 
(affected) individuals. We used 30 control individuals as a compromise between cost and efficiency, (1) 
because our approach proved successful with the given numbers, and (2) to obtain a p-value potentially 
smaller than 0.05 given that we include the observed data in our null data. Applied to our six patients and 
Figure 1. Pedigree drawings for families F1, F4, F6, OI, and L1. For families F1, F4, and F6, genotypes 
are marked for individuals with DNA available and tested; the following abbreviations are used: + , normal 
(wild-type) variant; Δ , rare mutant variant. Family OI: The affected individual (P1) is indicated with a solid 
symbol, heterozygotes are shown with half-solid symbols.
Family Gene Disease rank m % p
F1 TTC7A Multiple intestinal atresia 1 10 10.0 0.0645
F4 TTC7A Multiple intestinal atresia 1 14 7.1 0.0645
F6 TTC7A Multiple intestinal atresia 1 18 5.6 0.0645
OI BMP1 Osteogenesis imperfecta 1 14 7.1 0.0303
L1a POLR3B Leukodystrophy 1 50 2.0 0.0645
L1b POLR3B Leukodystrophy 4 44 9.1 0.0645
Table 1. Results of our family-control analysis for prioritizing m final candidate variants in an affected 
individual from five families. Rank = order of test statistic (largest tmax ranked 1) for pathogenic variant 
among the m candidate variants; % = top percentile rank, 100 × rank/m; p = empirical significance level. L1a 
and L1b refer to two affected individuals in family L1.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:12028 | DOi: 10.1038/srep12028
corresponding control individuals, the HDR method narrowed down the original number of shortlisted 
candidate variants to more than tenfold smaller lists.
Methods
Pathogenic mutations. Families F1/F4/F6. A pathogenic variant for multiple intestinal atresia18 was 
found in three affected individuals from three different families. It is a homozygous mutation for a 
four-base intronic deletion on chromosome 2 at positions 47,221,651-47,221,654 in the TTC7A gene, 
immediately adjacent to a consensus GT splice donor site.
Family OI. A pathogenic variant for osteogenesis imperfecta12 was observed in an affected individual. 
It is a homozygous missense mutation, T > C, at position 22,058,957 on chromosome 8 in the UTR3 
region of the BMP1 gene.
Family L1. A pathogenic variant for leukodystrophy13 was observed in an affected brother-sister pair 
in this small family. It is a missense mutation, rs138249161, at position 106,432,421 on chromosome 12 
in the POLR3B gene.
Sequencing protocol. Whole exome library preparation, capturing, sequencing and bioinformatics 
analyses were performed at the Genome Québec Innovation Center, Montreal, Canada, as detailed in 
our previous publications (see main text). In brief, 3 micrograms of DNA of 65 individuals were used 
for exome capture and sequencing. For each exome, the Burroughs Wheeler alignment (BWA) version 
0.5.919 was used to align the sequencing reads (100 bp paired-end) to the human reference sequence 
(hg19). Alignments were converted with SamTools19 from SAM format to sorted, indexed BAM files. 
Regions surrounding potential indels were realigned with the GATK IndelRealigner tool20. Picard-tools 
were used to remove invalid alignments and duplicate reads from the BAM files19. Single nucleotide vari-
ant (SNV) and indel variants were called with Samtools (v. 0.1.17) mpileup and were then quality filtered 
so that at least 20% (SNVs) or 15% (Indels) of reads supported the variant calls. All called variants were 
annotated with the ANNOVAR program21 to identify exonic or splicing or UTR variants, allele frequency 
in the 1000 Genomes Project22, Exome Variant Server (EVS, version 6500) and dbSNP (version 135), 
SIFT, PolyPhen-2 and PHASTCONS scores.
Web Resources
HDR program
http://www.gi.med.osaka-u.ac.jp/software/hdr/
ANNOVAR Software
http://www.openbioinformatics.org/annovar/
Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) http://evs.gs.washington.edu/EVS/
GATK Software
http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit
Maxstat program
http://lab.rockefeller.edu/ott/programs
PVALUES program
http://www.jurgott.org/linkage/util.htm#pvalues
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